Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2022
11 Janeiro 2023 - 9:30AM
via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water
technology company providing filtration solutions to the medical
and commercial markets, today announced preliminary revenue results
for the fourth quarter and fiscal year ended December 31, 2022.
Net revenue for the quarter ended December 31, 2022, is expected
to be approximately $2.6 million, a 6% quarter-over-quarter
increase and a 6% decrease from the quarter ended December 31,
2021. Full-year 2022 net revenue is expected to be approximately
$10.0 million, a 2% decrease over 2021.
"Nephros certainly faced some headwinds in 2022, but we ended
the year on a strong positive note, with sequential revenue growth,
record Active Customer Sites (ACS), and significantly improved net
cash flow," said Andy Astor, President and Chief Executive Officer.
“Quarter-over-quarter revenue increased 6% in the fourth quarter,
ACS increased to a new record of 1,394, and our net cash flow for
the second half of the year was approximately negative $500,000,
compared to negative $2.9 million in the first half.”
Nephros ended the fourth quarter with approximately $3.6 million
in cash on a consolidated basis.
The company will announce its fourth quarter and fiscal 2022
results on Wednesday, March 8, 2023, after market close and host a
conference call that same day at 4:30pm ET.
About Nephros
Nephros is committed to improving the human relationship with
water through leading, accessible technology. We provide innovative
water filtration products and services, along with water-quality
education, as part of an integrated approach to water safety.
Nephros goods serve the needs of customers within the healthcare
and commercial markets, offering both proactive and emergency
solutions for water management.
For more information about Nephros, please visit us at
nephros.com.
Forward-Looking Statements
This release contains forward-looking statements that are
subject to various risks and uncertainties. Such statements include
statements regarding Nephros’ expected revenue and cash flows for
the quarter and year ended December 31, 2022, expected future
revenue growth and the timing of such growth, and other statements
that are not historical facts, including statements that may be
accompanied by the words “intends,” “may,” “will,” “plans,”
“expects,” “anticipates,” “projects,” “predicts,” “estimates,”
“aims,” “believes,” “hopes,” “potential” or similar words. Actual
results could differ materially from those described in these
forward-looking statements due to certain factors, including the
impact of the ongoing COVID-19 pandemic, changes in business,
Nephros’ ability to further develop its sales organization,
inflationary factors and other economic and competitive conditions,
the availability of capital when needed, dependence on third-party
manufacturers and researchers, and regulatory reforms. These and
other risks and uncertainties are detailed in Nephros’ reports
filed with the U.S. Securities and Exchange Commission. Nephros
does not undertake any responsibility to update the forward-looking
statements in this release.
Investor Relations Contacts:Kirin Smith, PresidentPCG
Advisory, Inc.(646) 823-8656ksmith@pcgadvisory.com
Andy Astor, CEONephros, Inc.(201) 343-5202
x120andy.astor@nephros.com
Nephros (NASDAQ:NEPH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Nephros (NASDAQ:NEPH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024